Correlation between Lipoprotein(a) and Endometrial Cancer Prognosis: a Retrospective Cohort Study
Endometrial cancer (EC) is a malignant tumor arising from the endometrial epithelium and is among the most prevalent gynecological malignancies worldwide. Increasing evidence suggests that lipid profiles, hyperglycemia, and other metabolic factors play a role in EC pathogenesis. However, research on the association between lipoprotein(a) [Lp(a)] levels and EC prognosis remains limited. This retrospective cohort study analyzed Lp(a) levels in patients diagnosed with EC at Ganzhou Hospital, affiliated with Nanchang University, between January 2017 and January 2022. Lp(a) concentrations were measured post-admission, and patient prognosis was categorized as favorable or poor. Multivariate logistic regression analysis was performed to determine the adjusted odds ratio (OR) and 95% confidence interval (CI). The study included 296 EC patients, out of whom 72.3% (214/296) had a favorable prognosis, defined as no recurrence within five years post-surgery. The overall healing rate was 72.3% (214/296). When stratified by Lp(a) levels, patients in the first quantile (Q1 ≤ 122.2 g/L) had a favorable prognosis rate of 77.7% (115/148), whereas those in the second quantile (Q2 > 122.2 g/L) had a rate of 66.9% (99/148), with a statistically significant difference between groups (p < 0.05). In the multivariate regression model, the log2-transformed Lp(a) values and their corresponding ORs (95% CIs) for prognosis at two upper normal limits (ULN) were 1.7248 (1.0288 - 2.8918) and 2.0365 (1.1843 - 3.5018), respectively. Interaction analysis indicated that Lp(a) levels significantly influenced EC prognosis. Lp(a) is strongly associated with EC prognosis and holds potential clinical significance. Further studies are required to validate these findings.